NanoString Announces New PanCancer Immune Panel

The panel, developed in collaboration with immunooncology scientists around the world, including at INSERM, will help researchers create a profile of the human immune response in all cancer types.

NanoString Technologies Inc. (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products today announced the introduction of a new highly multiplexed gene expression panel for the nCounter® Analysis System the PanCancer Immune Profiling Panel. This novel panel will enable researchers to create profiles of the human immune response in all cancer types potentially accelerating the discovery and development of drugs therapies and predictive biomarker signatures for immunotherapy treatment response.

The growing field of Immuno-oncology aimed at leveraging the body’s ability to generate an effective immune response against cancer has seen a surge of progress in recent years. New discoveries immunotherapy drugs and promising ongoing clinical trials have intensified the focus on this area of cancer research. NanoString’s PanCancer Immune Profiling Panel is designed to provide researchers with a novel tool to help facilitate new advancements in key research areas including targeting of checkpoint blockades development of chimeric antigen receptors (CARs) for T-cell therapy and the identification of adjuvants for stimulating the immune response in the tumor microenvironment.

Read the complete press release: